Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?

about

Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?

Item

http://www.wikidata.org/entity/Q38737970

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Monoclonal antibody therapy in ...... stand and where are we going?

@en

type

Item

label

Monoclonal antibody therapy in ...... stand and where are we going?

@en

prefLabel

Monoclonal antibody therapy in ...... stand and where are we going?

@en

P1476

Monoclonal antibody therapy in ...... stand and where are we going?

@en

P2093

Carolina Schinke

http://www.w3.org/2001/XMLSchema#string

Christoph J Heuck

http://www.w3.org/2001/XMLSchema#string

Faith E Davies

http://www.w3.org/2001/XMLSchema#string

Gareth J Morgan

http://www.w3.org/2001/XMLSchema#string

Joshua Epstein

http://www.w3.org/2001/XMLSchema#string

Niels Weinhold

http://www.w3.org/2001/XMLSchema#string

Pankaj Mathur

http://www.w3.org/2001/XMLSchema#string

Sharmilan Thanendrarajan

http://www.w3.org/2001/XMLSchema#string

P2860

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

P304

367-384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT.15.118

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26888183

http://www.w3.org/2001/XMLSchema#string